ERBB2 and breast carcinoma: After successfully developing the 99mTc-NM-02 MI tracer with NM-02 NB as the lead compound [59], Zhao et al. recently investigated whether labeling said NB with 131I may be employed as a targeted radionuclide treatment agent for HER2+ breast cancer in xenografted mice [88].